Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

FEATURED COMPANY

stocks-making-the-biggest-moves-midday:-apple,-micron-technology,-coherent,-draftkings,-jm.-smucker-&-more

Stocks making the biggest moves midday: Apple, Micron Technology, Coherent, DraftKings, J.M. Smucker & more

Jun 10, 2026

Here are the companies making headlines in midday trading. Semiconductor stocks — Chip manufacturers slid as the tech…

Read more
3-dirt-cheap-stocks-to-buy-with-$1,000-right-now

3 Dirt-Cheap Stocks to Buy With $1,000 Right Now

Jun 10, 2026

There are still bargains to be had, even in a market that continues to climb the proverbial wall…

Read more
4-stocks-to-watch-on-tuesday:-jblu,-gsk,-pfe,-novt

4 stocks to watch on Tuesday: JBLU, GSK, PFE, NOVT

Jun 10, 2026

Stock market futures rise as tech rebounds and SpaceX IPO nears.

Read more
3-reasons-to-avoid-mov-and-1-stock-to-buy-instead

3 Reasons to Avoid MOV and 1 Stock to Buy Instead

Jun 9, 2026

The past six months have been a windfall for Movado’s shareholders. The company’s stock price has jumped 83.1%,…

Read more
global-dividend-stocks-featuring-fujita-engineering-and-2-more-top-picks

Global Dividend Stocks Featuring Fujita Engineering And 2 More Top Picks

Jun 9, 2026

As global markets navigate mixed economic signals, from resilient U.S. job growth to fluctuating oil prices and geopolitical…

Read more
gsk-in-talks-to-acquire-nuvalent-for-more-than-$9-billion-in-biggest-deal-in-over-a-decade:-ft

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

Jun 9, 2026

GlaxoSmithKline headquarters in London on Jan. 17, 2022. Hannah Mckay | Reuters Britain’s second-largest drugmaker GSK has entered…

Read more
phase-2-oncology-drug-developer-starton-holdings-decreases-shares-offered-by-25%-ahead-of-$30-million-ipo

Phase 2 oncology drug developer Starton Holdings decreases shares offered by 25% ahead of $30 million IPO

Jun 9, 2026

Starton Holdings, a Phase 2 developer of controlled release formulations for an approved cancer drug, lowered the proposed…

Read more
as-ibm-unlocks-a-‘multi-billion-dollar-opportunity’-with-google,-the-stock-is-a-buy

As IBM Unlocks a ‘Multi-Billion-Dollar Opportunity’ With Google, The Stock Is a Buy

Jun 9, 2026

A concept image of a neon pink circuit board_ Image by Gorodenkoff via Shutterstock_ Among the big technology…

Read more
1-oversold-stock-set-for-a-comeback-and-2-that-underwhelm

1 Oversold Stock Set for a Comeback and 2 That Underwhelm

Jun 9, 2026

Radek Strnad Mon, June 8, 2026 at 10:13 AM EDT 3 min read The past year hasn’t been…

Read more
3-hyped-up-stocks-we’re-skeptical-of

3 Hyped Up Stocks We’re Skeptical Of

Jun 9, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it…

Read more
3-reasons-h-is-risky-and-1-stock-to-buy-instead

3 Reasons H is Risky and 1 Stock to Buy Instead

Jun 9, 2026

Since June 2021, the S&P 500 has delivered a total return of 74.9%. But one standout stock has…

Read more
3-reasons-we-love-amphenol-(aph)

3 Reasons We Love Amphenol (APH)

Jun 9, 2026

Amphenol currently trades at $143.25 per share and has shown little upside over the past six months, posting…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 14
  6. 15
  7. 16
  8. 17
  9. 18
  10. 19
  11. 20
  12. ...
  13. 222
  14. »

Posts pagination

Newer posts Page 1 … Page 17 … Page 222 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.